Artificial Intelligence Algorithm for Subclinical Breast Cancer Detection
JAMA Network Open · 03.10.2024 · 7 (10) · e2437402
DOI: 10.1001/jamanetworkopen.2024.37402 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 03.10.2024. Verfasst von Jonas Gjesvik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: Breast Neoplasms, Artificial Intelligence, Algorithms, Early Detection of Cancer. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Early breast cancer detection is associated with lower morbidity and mortality.
Objective
To examine whether a commercial artificial intelligence (AI) algorithm for breast cancer detection could estimate the development of future cancer. Design, Setting, and Participants This retrospective cohort study of 116 495 women aged 50 to 69 years with no prior history of breast cancer before they underwent at least 3 consecutive biennial screening examinations used scores from an AI algorithm (INSIGHT MMG, version 1.1.7.2; Lunit Inc; used September 28, 2022, to April 5, 2023) for breast cancer detection and screening data from multiple, consecutive rounds of mammography performed from September 13, 2004, to December 21, 2018, at 9 breast centers in Norway. The statistical analyses were performed from September 2023 to August 2024. Exposure Artificial intelligence algorithm score indicating suspicion for the presence of breast cancer. The algorithm provided a continuous cancer detection score for each examination ranging from 0 to 100, with increasing values indicating a higher likelihood of cancer being present on the current mammogram. Main Outcomes and Measures Maximum AI algorithm score for cancer detection and absolute difference in score among breasts of women developing screening-detected cancer, women with interval cancer, and women who screened negative.
Results
The mean (SD) age at the first study round was 58.5 (4.5) years for 1265 women with screening-detected cancer in the third round, 57.4 (4.6) years for 342 women with interval cancer after 3 negative screening rounds, and 56.4 (4.9) years for 116 495 women without breast cancer all 3 screening rounds. The mean (SD) absolute differences in AI scores among breasts of women developing screening-detected cancer were 21.3 (28.1) at the first study round, 30.7 (32.5) at the second study round, and 79.0 (28.9) at the third study round. The mean (SD) differences prior to interval cancer were 19.7 (27.0) at the first study round, 21.0 (27.7) at the second study round, and 34.0 (33.6) at the third study round. The mean (SD) differences among women who did not develop breast cancer were 9.9 (17.5) at the first study round, 9.6 (17.4) at the second study round, and 9.3 (17.3) at the third study round. Areas under the receiver operating characteristic curve for the absolute difference were 0.63 (95% CI, 0.61-0.65) at the first study round, 0.72 (95% CI, 0.71-0.74) at the second study round, and 0.96 (95% CI, 0.95-0.96) at the third study round for screening-detected cancer and 0.64 (95% CI, 0.61-0.67) at the first study round, 0.65 (95% CI, 0.62-0.68) at the second study round, and 0.77 (95% CI, 0.74-0.79) at the third study round for interval cancers. Conclusions and Relevance In this retrospective cohort study of women undergoing screening mammography, mean absolute AI scores were higher for breasts developing vs not developing cancer 4 to 6 years before their eventual detection. These findings suggest that commercial AI algorithms developed for breast cancer detection may identify women at high risk of a future breast cancer, offering a pathway for personalized screening approaches that can lead to earlier cancer diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Radiology, University of Washington School of Medicine, Seattle.
- Fred Hutchinson Cancer Center, Seattle, Washington.
- Division of Biostatistics, Department of Public Health Sciences, University of California, Davis.
- Kaiser Permanente Washington Health Research Institute, Seattle.
- Department of Health and Care Sciences, Faculty of Health Sciences, The Arctic University of Norway, Tromsø, Norway.
Förderung
- NCI NIH HHS
Zitieren
APA
Gjesvik, J., Moshina, N., Lee, C. I., Miglioretti, D. L., & Hofvind, S. (2024). Artificial Intelligence Algorithm for Subclinical Breast Cancer Detection. JAMA Network Open, 7(10), e2437402. https://doi.org/10.1001/jamanetworkopen.2024.37402
Vancouver
Gjesvik J, Moshina N, Lee CI, Miglioretti DL, Hofvind S. Artificial Intelligence Algorithm for Subclinical Breast Cancer Detection. JAMA Network Open. 2024;7(10):e2437402. doi:10.1001/jamanetworkopen.2024.37402
BibTeX
@article{Gjesvik2024,
author = {Gjesvik, Jonas and Moshina, Nataliia and Lee, Christoph I and Miglioretti, Diana L and Hofvind, Solveig},
title = {Artificial Intelligence Algorithm for Subclinical Breast Cancer Detection},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {10},
pages = {e2437402},
doi = {10.1001/jamanetworkopen.2024.37402}
}
EUVIMED